[Synthetic antithyroid drugs and Basedow's disease or the choice of a therapeutic strategy]
- PMID: 1710802
[Synthetic antithyroid drugs and Basedow's disease or the choice of a therapeutic strategy]
Abstract
We present the conclusions of two prospective studies of patients examined at their first manifestation of Graves' disease and treated with antithyroid drugs (ATD). The purpose of the first study was to investigate the effects of long-term treatment: the patients were given carbimazole in degressive doses without hormone replacement for 18 months, the followed up for 2 to 6 years after drug withdrawal. The second study was designed to determine the effect of treatment duration on the prognosis: the patients were given an ATD according to the same protocol for a duration randomly set at either 6 or 18 months, then seen again 2 years after ATD withdrawal. The results showed that after 18 months of treatment at least 50 percent of the patients could be expected to remain in remission for 6 years. Remissions were less frequent when treatment was shorter (41.7 percent after the 6 month treatment versus 61.8 percent after the 18 month treatment, with a 2 years' follow-up; P less than 0.05). The relapses that occurred came early: 70 percent of them took place within the first post-treatment month. This article also provides evidence of high T3 and/or T4 levels without signs of thyrotoxicosis during the post-treatment clinical course; these exclusively biochemical relapses spontaneously disappeared and may have been expressing epidoses of active thyroiditis.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug.N Engl J Med. 1996 Jan 25;334(4):220-4. doi: 10.1056/NEJM199601253340403. N Engl J Med. 1996. PMID: 8531998 Clinical Trial.
-
[Improvement of the prognosis of Basedow's disease by using high doses of carbimazole].Presse Med. 1988 Jun 4;17(22):1124-7. Presse Med. 1988. PMID: 2969532 French.
-
A randomized trial of short-term treatment of Graves' disease with high-dose carbimazole plus thyroxine versus low-dose carbimazole.Clin Endocrinol (Oxf). 1998 May;48(5):585-92. doi: 10.1046/j.1365-2265.1998.00446.x. Clin Endocrinol (Oxf). 1998. PMID: 9666870 Clinical Trial.
-
[Treatment of Basedow disease with synthetic antithyroid drugs. Evaluation of the dose on the efficacy of the long term treatment].Ann Endocrinol (Paris). 1994;55(1):11-4. Ann Endocrinol (Paris). 1994. PMID: 7528485 Review. French.
-
Strategy for antithyroid drug therapy in Graves' disease.Horm Res. 1987;26(1-4):146-53. doi: 10.1159/000180694. Horm Res. 1987. PMID: 2439428 Review.
Cited by
-
Does smoking increase relapse rates in Graves' disease?J Endocrinol Invest. 2002 Feb;25(2):152-7. doi: 10.1007/BF03343979. J Endocrinol Invest. 2002. PMID: 11929086
-
Comparison of methimazole/hydrocortisone ointment with oral methimazole in patients with graves disease: A prospective, randomized, open-label, parallel-group, 18-month study.Curr Ther Res Clin Exp. 2008 Aug;69(4):305-17. doi: 10.1016/j.curtheres.2008.08.004. Curr Ther Res Clin Exp. 2008. PMID: 24692808 Free PMC article.
-
Antithyroid drug regimen for treating Graves' hyperthyroidism.Cochrane Database Syst Rev. 2010 Jan 20;2010(1):CD003420. doi: 10.1002/14651858.CD003420.pub4. Cochrane Database Syst Rev. 2010. PMID: 20091544 Free PMC article.
-
Excessive iodine intake does not increase the recurrence rate of graves' disease after withdrawal of the antithyroid drug in an iodine-replete area.Eur Thyroid J. 2015 Mar;4(1):36-42. doi: 10.1159/000375261. Epub 2015 Mar 4. Eur Thyroid J. 2015. PMID: 25960960 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials